Serum-soluble receptor for advanced glycation end-products values might have diagnostic and prognostic significances in ulcerative colitis

Authors : Irfan Küçük, Ersin Tural, Yusuf Yazgan, Başak Çakir Güney, Idris Yildirim, Tuğba Akbaş Şimşek, Musa Salmanoğlu

Pages : 1398-1404

Doi:10.32322/jhsm.1343016

View : 41 | Download : 99

Publication Date : 2023-10-29

Article Type : Research Paper

Abstract :Aims: There is evidence of anti-inflammatory qualities associated with a soluble receptor for advanced glycation end products (sRAGE). We aimed to evaluate whether serum sRAGE levels of patients with inflammatory bowel diseases (IBDs) could serve as a biomarker by utilizing several clinical and laboratory models of disease activity for these individuals. Methods: This case-control study included 77 ulcerative colitis (UC) patients (51 males and 26 females), 49 Crohn’s disease (CD) patients (33 males and 16 females) and 54 healthy controls (38 males and 16 females). In UC, the UC Mayo Clinical Scoring system (MCS) was used for the clinical and endoscopic features. The histological activity index (HAI) of UC patients was determined by Truelove and Richards method. The Crohn\'s disease activity index (CDAI) was utilized for CD patients. Results: In comparison to the control group, the median sRAGE concentrations in UC patients were significantly lower. [911.17 ng/L (322.91-1682.19 vs 1420.96 ng/L (816.68-2320.08), respectively, p=0.008)]. The patients with CD did not significantly differ from the other groups. The MCS and HAI values of UC patients negatively correlated to the serum sRAGE values (rho=-0,610, p<0.001 vs rho=-0,742 respectively, p<0.001). CD patients in remission had higher sRAGE values than patients having active disease [1720.42 ng/L (1005.68-2414.41) vs. 923.36 ng/L (601.61-1361.22 respectively, p=0.002]. CD patients under treatment had higher sRAGE values than patients without any treatment [1361.22 ng/L (821.26-1944.2) vs. 879.38 ng/L (601.61-1239.41) respectively, p=0.033] Conclusion: Serum sRAGE might be an auxiliary biomarker for the clinical and laboratory traits of UC.
Keywords : Ulcerative colitis, receptor, advanced glycation end products